Clinical Trials Browser

Phase 2 × Adenocarcinoma × trastuzumab deruxtecan × Clear all

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04989816 2024-11-21

DG-06

Phase 2 Completed

95 enrolled 22 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Phase 2 Completed

233 enrolled 26 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms